Investment Analysts’ Recent Ratings Changes for Iqvia (IQV)

Iqvia (NYSE: IQV) recently received a number of ratings updates from brokerages and research firms:

  • 10/25/2018 – Iqvia was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “IQVIA Holdings reported solid third-quarter 2018 results wherein the company’s earnings and revenues surpassed the Zacks Consensus Estimate. The company serves the life sciences industry with the help of advanced analytics, technology solutions and contract research services. With its increasing presence in emerging markets, IQVIA Holdings should benefit from the evolving growth opportunities in the life sciences industry. The company offers an extensive range of technology solutions in the form of cloud-based applications. It attempts to help its clients gain a deep understanding of the entire healthcare system and its related processing, with the help of real-world data. IQVIA Holdings’ endeavors to reward its shareholders look impressive. The company outperformed its industry in the past year. However, a debt-laden balance sheet remains a concern. Extensive global presence exposes the company to foreign currency exchange risk.”
  • 10/23/2018 – Iqvia had its price target raised by analysts at Barclays PLC from $130.00 to $140.00. They now have an “overweight” rating on the stock.
  • 10/23/2018 – Iqvia had its price target raised by analysts at Royal Bank of Canada to $137.00. They now have an “outperform” rating on the stock.
  • 10/23/2018 – Iqvia had its price target raised by analysts at Piper Jaffray Companies to $131.00. They now have a “neutral” rating on the stock.
  • 10/23/2018 – Iqvia was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $142.00 price target on the stock. According to Zacks, “IQVIA Holdings reported solid third-quarter 2018 results wherein the company’s earnings and revenues surpassed the Zacks Consensus Estimate. The company serves the life sciences industry with the help of advanced analytics, technology solutions and contract research services. With its increasing presence in emerging markets, IQVIA Holdings should benefit from the evolving growth opportunities in the life sciences industry. The company offers an extensive range of technology solutions in the form of cloud-based applications. It attempts to help its clients gain a deep understanding of the entire healthcare system and its related processing, with the help of real-world data. IQVIA Holdings’ endeavors to reward its shareholders look impressive. The company outperformed its industry in the past year. However, a debt-laden balance sheet remains a concern. Extensive global presence exposes the company to foreign currency exchange risk.”
  • 10/9/2018 – Iqvia is now covered by analysts at UBS Group AG. They set a “buy” rating on the stock.
  • 10/2/2018 – Iqvia had its price target raised by analysts at Robert W. Baird from $143.00 to $146.00. They now have an “outperform” rating on the stock.

Shares of IQV traded up $0.70 during trading on Tuesday, reaching $122.37. 775,203 shares of the company traded hands, compared to its average volume of 1,270,164. Iqvia Holdings Inc has a twelve month low of $91.57 and a twelve month high of $135.48. The stock has a market cap of $24.62 billion, a PE ratio of 28.07, a P/E/G ratio of 1.75 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09.

Iqvia (NYSE:IQV) last announced its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business had revenue of $2.59 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts expect that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In related news, Director John G. Danhakl sold 370,470 shares of Iqvia stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total value of $46,245,770.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John G. Danhakl sold 221,900 shares of Iqvia stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $126.63, for a total transaction of $28,099,197.00. The disclosure for this sale can be found here. Insiders sold 601,586 shares of company stock valued at $75,510,422 in the last 90 days. Company insiders own 6.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in IQV. Cutler Group LP grew its holdings in shares of Iqvia by 173.3% in the second quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 2,600 shares in the last quarter. Townsend & Associates Inc acquired a new position in shares of Iqvia in the second quarter valued at approximately $117,000. Fort L.P. acquired a new position in shares of Iqvia in the second quarter valued at approximately $118,000. Hamilton Lane Advisors LLC acquired a new position in shares of Iqvia in the third quarter valued at approximately $121,000. Finally, Quad Cities Investment Group LLC acquired a new position in shares of Iqvia in the second quarter valued at approximately $140,000. Hedge funds and other institutional investors own 91.36% of the company’s stock.

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Cash Flow Analysis in Stock Selection

Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply